Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)Recruiting
NCT04728893Phase 2Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Hematologic Malignancies · Waldenstroms Macroglobulinaemia · Non-Hodgkins Lymphoma · Chronic Lymphocytic Leukaemia
United States, Argentina, Australia, Brazil, Canada +17 more
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)Recruiting
NCT07431827Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Argentina, Australia, Canada, China, France +8 more
Sac-TMT for Active TNBC Brain MetastasesNot Yet Recruiting
NCT07458113Phase 2Updated Jul 24, 2026
Sponsor: Yale University
Metastatic Triple Negative Breast Cancers
United States
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Recruiting
NCT03486873Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Solid Tumors · Hematologic Malignancies
United States, Argentina, Australia, Austria, Belgium +46 more
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)Recruiting
NCT07340827Phase 3Updated Jul 24, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Infertility
Japan
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).Recruiting
NCT06655324Phase 1Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)Recruiting
NCT07549412Phase 3Updated Jul 24, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Metastatic Colorectal Cancer
United States, Australia, Canada, Japan, South Korea +1 more
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Recruiting
NCT06136624Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Prostate Cancer Metastatic
United States, Argentina, Australia, Austria, Brazil +31 more
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Recruiting
NCT07058077Phase 2, Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Heterozygous Familial Hypercholesterolemia (HeFH)
United States, Australia, Belgium, Brazil, Chile +10 more
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Recruiting
NCT06997497Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Colon Adenocarcinoma · Rectal Adenocarcinoma
United States, Argentina, Australia, Brazil, Canada +23 more
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Active Not Recruiting
NCT04634877Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Endometrial Neoplasms
United States, Argentina, Austria, Belgium, Canada +23 more
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)Recruiting
NCT07405151Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Oesophageal Squamous Cell Carcinoma
United States, Brazil, China, Czechia, Japan +5 more
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Recruiting
NCT05139017Phase 2, Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
DLBCL · Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Brazil, Canada +21 more
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)Recruiting
NCT06445972Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Esophageal Cancer
United States, Brazil, Chile, China, France +6 more
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)Recruiting
NCT07209111Phase 2Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Neoplasm Malignant
United States, Australia, Canada, Chile, China +13 more
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced SarcomaActive Not Recruiting
NCT04874311Phase 2Updated Jul 24, 2026
Sponsor: Institut Bergonié
Advanced Soft-tissue Sarcoma · Metastatic Soft-tissue Sarcoma
France
A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano [VPH]")Not Yet Recruiting
NCT07706673N/AUpdated Jul 23, 2026
Sponsor: National Cancer Institute (NCI)
Human Papillomavirus-Related Malignant Neoplasm
Costa Rica
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Recruiting
NCT07060807Phase 3Updated Jul 23, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Brazil, Canada +21 more
Genitourinary Tumors With Sacituzumab TirumotecanNot Yet Recruiting
NCT07716917Phase 2Updated Jul 23, 2026
Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Papillary Renal Carcinoma · Variant Histology Urothelial Carcinoma
Spain
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruiting
NCT07332481Phase 3Updated Jul 23, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Systemic Lupus Erythematosus (SLE) · Cutaneous Lupus Erythematosus (CLE)
United States, Japan
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)Terminated
NCT06022757Phase 1, Phase 2Updated Jul 23, 2026
Sponsor: Evopoint Biosciences Inc.
Carcinoma · Squamous Cell Carcinoma of Head and Neck · Urothelial Carcinoma · Prostate Cancer
China
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPDActive Not Recruiting
NCT07016412Phase 2Updated Jul 23, 2026
Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease
United States
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Recruiting
NCT06463587Phase 3Updated Jul 23, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Generalized Myasthenia Gravis
United States, Argentina, Australia, Belgium, Bulgaria +19 more
Improving Vaccine Acceptance Through EHR Integrated Patient- and Provider-Facing Decision SupportRecruiting
NCT06482450NAUpdated Jul 23, 2026
Sponsor: Johns Hopkins Bloomberg School of Public Health
Vaccine Hesitancy · Vaccine Refusal
United States
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)Not Yet Recruiting
NCT07722611Phase 2, Phase 3Updated Jul 23, 2026
Sponsor: Merck Sharp & Dohme LLC
Polycythemia Vera

Previous page Next page